In 2017, the FDA approved the first medication Abilify MyCite (aripiprazole tablets with sensor, Otsuka America Pharmaceutical).
The sensor, developed by Proteus Digital Health, talks with a patch on the torso that sends data to a mobile phone app. The patch also tracks steps, heart rate, respiration, and sleep activity that provides an accurate pattern of adherence.
The system has been tested with medications for hypertension, heart failure, diabetes, tuberculosis, bipolar affective disorder, and schizophrenia.
Image courtesy of Otsuka America Pharmaceutical, Inc.